COG vs. RENX, INHC, FDBK, TRLS, IQAI, DVRG, SENS, EMIS, CRW, and INS
Should you be buying Cambridge Cognition stock or one of its competitors? The main competitors of Cambridge Cognition include Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), Trellus Health (TRLS), IQ-AI (IQAI), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.
Cambridge Cognition vs. Its Competitors
Cambridge Cognition (LON:COG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
Cambridge Cognition has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
35.2% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 28.4% of Renalytix shares are owned by institutional investors. 29.9% of Cambridge Cognition shares are owned by insiders. Comparatively, 35.7% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cambridge Cognition received 82 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 44.30% of users gave Cambridge Cognition an outperform vote.
Cambridge Cognition has a net margin of -10.07% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Cambridge Cognition's return on equity.
In the previous week, Cambridge Cognition's average media sentiment score of 0.67 beat Renalytix's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the media.
Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Summary
Cambridge Cognition beats Renalytix on 8 of the 14 factors compared between the two stocks.
Get Cambridge Cognition News Delivered to You Automatically
Sign up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cambridge Cognition Competitors List
Related Companies and Tools
This page (LON:COG) was last updated on 6/14/2025 by MarketBeat.com Staff
Buy COG Stock Free COG Stock Alerts